Neuroendocrine activity was studied in 60 consecutive untreated patients with dyspnoea and a clinical suspicion of heart failure. On the basis of the socalled Boston clinical criteria the diagnosis of heart failure was regarded as unlikely in 26 patients, possible in 15 patients, and definite in 19 patients. These groups were studied before any drug treatment was started and were compared with a control group of 69 healthy individuals. Plasma atrial natriuretic peptide concentration was clearly raised in patients with definite heart failure and slightly raised in patients with possible heart failure.
The basic disturbance in heart failure is a defect in left ventricular pump function which results in inadequate blood flow to peripheral tissues. In advanced congestive heart failure, complex neuroendocrine mechanisms are activated in an attempt to compensate for the decreased cardiac output. These responses include release of atrial natriuretic peptide from cardiac myocytes,'-3 activation of the sympathetic nervous system,45 and activation of the renin-angiotensin-aldosterone system.6' Most studies of the hormonal changes in heart failure have included patients treated with diuretics; there is little information on the activation of the neuroendocrine system in untreated heart failure,9-2 especially on concentrations of atrial natriuretic peptide. We studied neuroendocrine activation in patients in whom the diagnosis of heart failure was suspected for the first time and in whom treatment for the condition had not been star- ted. We used the Boston diagnostic criteria"3 to confirm the clinical diagnosis of heart failure.
Patients and methods

PATIENTS
We studied 88 patients (37 men and 51 women) with a clinical suspicion of previously unrecognised heart failure and 82 controls (36 men and 46 women), all aged 45-74 years.
Patients were identified by 32 primary health care physicians working in community health centres in a defined area in eastern Finland. These physicians had agreed to refer to the university clinic all patients who had presented with symptoms or signs suggestive of heart failure and in whom this condition had not been previously diagnosed. Patients with acute pulmonary oedema complicating myocardial infarction were not included. Those 24 patients who had severe symptoms were referred immediately and studied on the day of referral, whereas the remaining 64 patients with milder symptoms were examined within two weeks of their visit to the primary health care centre. A detailed description of the patient series has been published elsewhere. '4 Twenty eight patients were excluded from hormone analyses: 21 because of current treatment with digitalis, diuretics, angiotensin converting enzyme inhibitors, or sympathomimetic drugs; three because of severe respiratory failure caused by pulmonary disease or kyphoscoliosis, and four because of other diseases with indications for immediate treatment such as acute bronchitis, acute fibrosing alveolitis, diabetic ketoacidosis, or pulmonary embolism. Thus 60 patients (23 men and 37 women) comprised the final patient population. All of them had dyspnoea or fatigue or both. Seven patients had atrial fibrillation and 53 were in sinus rhythm.
We identified 300 candidates for the control group by a random population sample of 45-74 year old inhabitants in the survey area. A mailed questionnaire was used to exclude persons with previously diagnosed heart failure, coronary heart disease, hypertension, arrhythmias, or other disabling conditions. Eighty eight persons were thus selected from the initial sample, but 19 of them were excluded after the study visit. The reasons for exclusion were bronchial asthma, coronary heart disease (15 cases), gastric carcinoma, hypertrophic cardiomyopathy, and Parkinson's disease. Thus the control group comprises 69 persons without any symptomatic cardiac or pulmonary disease or other obvious disease.
All examinations at the Kuopio University Central Hospital were performed before drug treatment for heart failure was started. The study was carried out from 1 June 1986 to 3 May 1988 and the patient and control series were examined in parallel over the study period. The study protocol was approved by the ethics committee of the University of Kuopio. Informed consent was obtained from each patient and control.
Methods
Clinical examination
One of us (JR) carried out the clinical examination and interpretation of conventional chest radiographs on all study subjects. The examination included a questionnaire on the patient's history of previous diseases and use of drugs. At the physical examination special attention was paid to signs of heart failure, such as the third heart sound, rales or wheezing on lung auscultation, raised jugular venous pressure, liver enlargement, or leg oedema. Weight and height were measured in light indoor clothing and body mass index was calculated as weight in kilograms per height in metres squared. A patient was considered to be non-obese if body mass index was < 27 kg/ m2 and obese if body mass index was > 27 kg/ m2. Blood pressure was measured in recumbent individuals with a sphygmomanometer after five minutes of supine rest and the average of two measurements at an interval of two minutes was used. Heart rate was obtained from the resting electrocardiogram and relative heart volume was estimated from the chest x ray according to the method of Jonsell.'5
Diagnostic classification
Information from clinical and radiographic examinations was used in the diagnostic classification of patients by a modification of the so-called Boston diagnostic criteria for heart failure. '3 14 In this scoring system points were given in three categories: for features in the history, for physical signs, and for radiographic signs suggestive of the presence of heart failure. Points were given in the first category for symptoms of dyspnoea and fatigue; in the second category for tachycardia, raised jugular venous pressure, lung rales or wheezing, and third heart sound; and in the third category for abnormal filling pattern of pulmonary veins, enlarged heart silhouette, pleural effusion, and evidence of interstitial or alveolar pulmonary oedema. A maximum of four points was allowed in each of the three categories, so a maximum score of 12 points was possible. Group 1 consisted of patients with a score of 0-4 points, defined as "unlikely to have heart failure". Patients with a score of 5-7 points were defined as having "possible heart failure" (group 2). Patients with a score of 8-12 points were defined as having "definite heart failure" (group 3).
A patient was considered to have coronary heart disease when one of the following criteria was fulfilled: (a) the patient had a history of myocardial infarction; (b) the patient had angina pectoris by the Rose questionnaire, '6 
Results
CLINICAL CHARACTERISTICS
Most patients were in New York Heart Association functional class I-III, and thus symptoms suggestive of heart failure were in general mild or moderate (table 1) . However, 10 patients (53%) in group 3 belonged to functional class IV. Twenty six patients (six men and 20 women) were classified "unlikely to have heart failure" (group 1). This shows that primary health care diagnosis of heart failure was more often incorrect in women than in men (p < 00 1).'" Obesity was common in all patient groups. There were signs of volume overload such as leg oedema, liver enlargement, or increased jugular venous pressure in four patients (15%) in group 1, six (40%) in group 2, and 13 (68%) in group 3.
Most patients had evidence of either coronary heart disease or hypertension and some were taking drugs for angina pectoris. According to the criteria used in this study, some of the control subjects also had hypertension as judged by a single blood pressure measurement. Coronary heart disease was more common in group 2 than in group 1. Hypertension was significantly more common in group 3 than in the control group or group 1, whereas no significant differences in frequencies of hyper- Remes, Tikkanen, Fyhrquist, Pyorald tension were seen between group 1, group 2, and the control group. The serum creatinine concentration was higher in group 3 than in any * other study group and serum sodium concen-* tration was lower in group 3 than in the control group (table 2) . In addition, the serum albumin concentration was lower in group 3 than in the *°control group or in group 1. No significant differences were seen in haematocrit between * the study groups.
ECHOCARDIOGRAPHY AND EXERCISE TESTING
The left atrial and left ventricular diameters _°-____ were greater and fractional shortening and peak C% rate of increase in left ventricular diameter were smaller in group 3 than in the control oup 3 group or in group 1 ( in the control group but they were not higher in group 3 than in group 1 or group 2 (figs 2 and 3). Plasma aldosterone concentration showed a wide range of variation in all study groups ( fig  4) . There was no significant difference between the study groups in plasma renin activity, which was considerably increased in only four patients ( fig 5) .
There were no significant differences in plasma hormone values between men and women, and no significant differences between non-obese and obese persons either in the entire patient population or within any of the study groups. The results were essentially the same when patients treated with f blockers, calcium antagonists, or long acting nitrates were excluded separately or altogether from the analysis. The results also remained unchanged when those controls who were defined as having hypertension were not included. Plasma atrial natriuretic peptide concentration was higher in patients who had signs of volume overload than in patients who had none of these signs (192 (23) pg/ml v 113 (35) pg/ml, p < 0 01 (all patients included)). However, even when only those patients in whom no signs of volume overload were seen were included in the analysis, plasma atrial natriuretic peptide concentration was still higher in group 3 than in group 1 (297 (81) pg/ml v 53 (7) pg/ml, p < 001). We found no significant differences between the study groups for any other hormones which are associated signs of volume overload. Table 5 shows the correlations of plasma hormone values with each other and with some other selected variables. All patients were included in these linear regression analyses. There was a positive correlation between plasma atrial natriuretic peptide, adrenaline, and noradrenaline concentrations. Plasma atrial natriuretic peptide concentration was also correlated positively with heart rate, relative heart volume, New York Heart Association functional class, and with left atrial and ventricular dimensions determined by echocardiography. Plasma atrial natriuretic peptide concentration was negatively correlated with fractional shortening, peak rate of increase in left ventricular diameter, and peak rate of oxygen consumption.
In group 3, there was a statistically significant inverse correlation between plasma atrial natriuretic peptide concentration and peak rate of increase in left ventricular diameter (r = -0-603, p < 0 01) and with peak rate of oxygen consumption (r = -0-966, p < 0 1). No other significant correlations were found within this group between plasma hormone values and the variables listed in table 5. We found no significant correlations between any of the plasma hormone measurements in the controls, but there was a weak inverse correlation between plasma adrenaline concentration and left ventricular end diastolic and end systolic diameters (r = -0-287, p < 0 01 and r = -0-289, p < 0 01, respectively).
We assessed the possible usefulness of plasma atrial natriuretic peptide measurement as a diagnostic test in confirming the presence or absence of "definite heart failure" by the Boston classification by using the upper limit of the 95% confidence interval in the control group (101 pg/ml) as the cut offvalue. This cutoff value had a sensitivity of 83% and a specificity of 85% in identifying patients belonging to group 3-that is, patients with "definite heart failure" (fig 1) . Furthermore, if the plasma concentration of atrial natriuretic peptide was above the cut off level, the probability that the patient belonged to group 3 was 71% (positive predictive value) and if the Several studies have shown that sympathetic nervous activity, as judged by measurement of plasma noradrenaline concentration, is increased in patients with heart failure during treatment with diuretics.
However, studies of sympathetic nervous activity in untreated heart failure have been contradictory. In a recent study, plasma noradrenaline concentration was not raised in patients with mild heart failure from whom cardiac medication had been withdrawn one week before the study.'0 Whereas plasma noradrenaline concentrations were raised in untreated patients with moderately severe9 or severe heart failure'2 and also in patients with asymptomatic left ventricular dysfunction." In our study, plasma adrenaline and noradrenaline concentrations were both significantly higher in patients with "definite" heart failure than in healthy controls. Thus our results accord with activation of the sympathetic nervous system early in the natural course of heart failure.
It is generally accepted that the activity ofthe renin-angiotensin-aldosterone system is increased in patients with advanced chronic heart failure treated with diuretics. 35 On the other hand, some previous studies based on small series of patients suggested that the renin angiotensin-aldosterone system would not be activated in patients with heart failure who have not received treatment with diuretics." 12 14 The results of the present study confirm that activation of this system is uncommon in untreated heart failure. However, because these findings apply to the activity of the renin-angiotensin-aldosterone system in circulating blood only they do not exclude the possibility that the tissue renin-angiotensin systems could be altered in heart failure.
We found that plasma atrial natriuretic peptide concentration was higher in those patients in whom there was a definite diagnosis of heart failure according to the Boston classification and that it was uncommon in patients who proved not to be in heart failure. We are cautious about drawing definite conclusions from this cross sectional study, but our findings do suggest that the measurement of plasma atrial natriuretic peptide might be helpful in the diagnostic evaluation of patients with suspected heart failure and that this measurement could be particularly useful in excluding heart failure.
